Short Title: Genotype-phenotype in FA-B complementation group 2 KEY POINTS • X-linked FANCB pathogenic variants predominantly cause acute, early onset bone marrow failure and severe congenital abnormalities • Biochemical and cell-based assays with patient variants reveal functional properties of FANCB that associate with clinical severity ABSTRACT Fanconi anemia (FA) is the most common genetic cause of bone marrow failure, and is caused by inherited pathogenic variants in any of 22 genes. Of these, only FANCB is X-linked. We describe a cohort of 19 children with FANCB variants, from 16 families of the International Fanconi Anemia Registry (IFAR). Those with FANCB deletion or truncation demonstrate earlier than average onset of bone marrow failure, and more severe congenital abnormalities compared to a large series of FA individuals in the published reports. This reflects the indispensable role of FANCB protein in the enzymatic activation of FANCD2 monoubiquitination, an essential step in the repair of DNA interstrand crosslinks. For FANCB missense variants, more variable severity is associated with the extent of residual FANCD2 monoubiquitination activity. We used transcript analysis, genetic complementation, and biochemical reconstitution of FANCD2 monoubiquitination to determine the pathogenicity of each variant. Aberrant splicing and transcript destabilization was associated with two missence variants. Individuals carrying missense variants with drastically reduced FANCD2 monoubiquitination in biochemical and/or cell-based assays showed earlier onset of hematologic disease and shorter survival. Conversely, variants with near-normal FANCD2 monoubiquitination were associated with more favorable outcome. Our study reveals a genotype-phenotype correlation within the FA-B complementation group of FA, where severity is linked to the extent of residual FANCD2 monoubiquitination.
INTRODUCTION
Fanconi anemia (FA) is an inherited disorder caused by DNA repair deficiency, which results in progressive bone marrow failure leading to aplastic anemia. FA is also associated with congenital abnormalities and a highly elevated risk of acute myeloid leukemia and head and neck cancers. 1 In a large series of patients, the average age at onset of hematological abnormalities was reported to be 7.6 years, 2 and about two-thirds of patients exhibit one or more congenital abnormalities. 3 At least 22 FA-causing genes have been identified, named FANCA-FANCW, 4 but only FANCB (MIM# 300515) is X-linked recessive. 5 This makes it especially important to identify FANCB variants as to pathogenicity, and whether de novo or not, in order to provide proper genetic counseling. Variants in FANCB account for ~4% of all male cases of FA, 6 and are often associated with severe congenital abnormalities resembling VACTERL (Vertebral abnormalities, Anal atresia, Cardiac defects, Tracheoesophageal fistula, Esophageal atresia, Renal abnormalities or Limb abnormalities) association with hydrocephalus. 7, 8 The course of hematological disease and severity of VACTERL-H or any genotype-phenotype correlations among FANCB individuals remains to be elucidated. FANCB protein is a component of the FA core complex that also contains the products of six other FANC genes (A, C, E, F, G and L) together with FA-associated proteins (FAAP100 and FAAP20). 9 The FA core complex is necessary to signal the existence of stalled replication forks, caused by DNA interstrand crosslinks (ICL), covalent bonds between Watson and Crick DNA strands. It is required for monoubiquitination of the DNA binding proteins FANCD2 and FANCI, which form the ID2 heterodimer. In particular, FANCB, FANCL, and FAAP100 are the critical minimal components required for in vitro monoubiquitination of ID2. 10, 11 While FANCL is the RING E3 ligase necessary for ubiquitination to occur, FANCB and FAAP100 play an enigmatic role in the reaction.
Very few studies have explored the function of the FANCB protein, despite its identification as a critical enzymatic component of the FA core complex. This is in part because the protein contains no known predicted domains, and also because it is intractable to work with in isolation. It was shown that co-expression and purification of a recombinant complex of FANCB, FANCL, and FAAP100 (BL100 complex) can overcome these difficulties, [10] [11] [12] and this reflects a similar interdependence of stability for these three proteins in human cells. 5, 13, 14 Recombinant BL100 complex is twice its predicted mass, reflective of a dimerization of the complex through the FANCB subunit. 11 BL100 can also interact independently with the CEF (FANCC, FANCE, FANCF) and AG20 (FANCA, FANCG, FAAP20) subcomplexes of the FA core complex. Here, through biochemical and cell-based assays we demonstrate FANCB's central role in the FA core complex assembly and activity, and establish how patient-associated variants disrupt DNA damage signaling in FA. We present molecular diagnosis, functional evaluation of the variants and clinical presentations of the largest cohort of individuals with FANCB variants yet described. We find that individuals with missense variants, in general, had a delayed onset of hematologic disease, and longer overall survival, which correlate with the extent of residual function retained by the variant FANCB protein.
METHODS

Study participants
The study subjects include individuals diagnosed with FA and their family members 
Identification of disease-causing FANCB variants
Genomic DNA was isolated from peripheral blood, fibroblast, or EBV-immortalized lymphoblastoid cell line (LCL). Targeted Nextgen sequencing, Sanger sequencing, array comparative genomic hybridization (aCGH) and SNP arrays were employed to identify sequence variants as described earlier, 15 and further outlined in supplemental methods.
Reverse transcription-PCR (RT-PCR)
Total RNA from individual-derived cell lines was obtained using RNeasy Plus Mini Kit (Qiagen). Complementary DNA (cDNA) synthesis was done using SuperScript TM III or IV First-Strand Synthesis System (Thermo Fisher Scientific). Screening for aberrant FANCB splice products was done as described further in supplemental methods.
Quantitative fluorescence PCR (qf-PCR)
A modified version of the previously described qf-PCR method was used to measure the relative levels of aberrant splice or missense product vs normal splice product. 16, 17 A FAMlabeled primer (M13F-FAM) was included to generate fluorescently labeled products. Primers to 5 generate splice products with similar sizes were designed and are listed in Table S1 . Details of PCR reactions are provided in supplemental methods.
Cell culture
Fibroblasts were cultured in DMEM (Gibco) plus 15% FBS (Atlanta Biologicals), 1% Pen Strep (Gibco), 1% GlutaMAX™ (Gibco) and 1% MEM non-essential amino acids (Gibco). LCLs were cultured in RPMI 1640 (Gibco) plus 20% FBS, 1% Pen Strep and 1% GlutaMAX™.
Fibroblast cell lines were transformed and/or immortalized by expression of HPV16 E6E7 and the catalytic subunit of human telomerase (hTERT), respectively.
Complementation of FANCB deficient cell lines with wild type (WT) or variant FANCB
The WT FANCB and missense variants cloning, lentiviral vector preparation, and complementation experiments were performed as described earlier, 18 and further outlined in supplemental methods.
Recombinant FANCB protein co-purification
FANCB variant was cloned into pFL-FANCB-FANCL-FAAP100, and purified protein was generated from resultant baculovirus as described in Swuec et al 12 and summarized in the supplemental methods.
In vitro ubiquitination experiments
All protein purifications and reactions were performed exactly as described in van Twest et al 11 and summarized in supplemental methods, substituting variant FANCB-containing BL100 complexes where appropriate. StrepII-FANCD2 and Flag-FANCI were detected with αStrepII tag (ab76949, Abcam) or αFlag-tag (OAEA00002, Aviva Systems Biology) antibodies.
Statistical analyses of clinical data
The statistical analyses of clinical data for time to death and time to hematologic disease were performed as outlined in supplemental methods.
RESULTS
A wide spectrum of inherited or de novo FANCB pathogenic variants cause FA
In a comprehensive effort towards molecular diagnosis of FA, we identified diseasecausing FANCB variants in 19 individuals from 16 families enrolled in the IFAR ( Figure 1A Table 1 ). The IFAR families were of varied race/ethnicity, including Caucasian, Hispanic and African-American. Table 1 describes the clinical information and genotype of these 19 individuals from the IFAR and two additional individuals (# 9 and 21) published previously by others. 8, 19 Among the 19 IFAR individuals, we observed two large deletions, 590kb (individuals 1-2) and 520kb (individual 3) encompassing the FANCB gene in two families. SNP arrays and aCGH showed that these deletions included the entire FANCB gene as well as an adjacent upstream gene, MOSPD2, and a downstream gene, GLRA2 ( Figure S1 ). Further, we identified sequence variants predicted to generate a truncated protein in 9 individuals, including two variants affecting splice junctions (individuals 4-5), three resulting in a nonsense codon (individuals 6-8), and four indels from three families (individuals 11-14). Individual 15 carried two overlapping de novo variants, a missense (NM_001018113:c.2249G>T; p.G750V) and an indel (NM_001018113:c.2249_2252delGAAG p.G750Vfs*5). The proportion of missense variant was observed to go down from 80% in blood to 53% in the LCL, suggesting positive growth selection for cells with indel variant (Table S2 ). Five individuals from four families carried missense variants (individuals [16] [17] [18] [19] [20] . All missense variants appeared in highly conserved residues across 99 FANCB orthologs ( Figure 1B , Table S3 ). Additionally, we previously reported individual #10, 18 who carried an unstable 9154 bp intragenic duplication, exhibiting mosaicism in both the proband and the carrier mother; this individual is not discussed further in this report. It is notable that each of the families in this study had a unique pathogenic variant, with no evidence for a common founder.
Availability of parental DNA for 13/16 IFAR families allowed us to infer the origin of the pathogenic variant. Nine were inherited (12 individuals) while four were presumed de novo (i.e. arose during gametogenesis in a parent, or very early in embryogenesis) ( Table 1) . We performed deep sequencing of the variant region in the proband and parents using MiSeq method (Table S4) . At a read depth in the range of 223,000-609,000, we confirmed the variants to be absent in the parents and de novo in the probands (Table S2 ). Despite being de novo in origin, blood mosaicism was not observed and the variant frequency was ~100% in three individuals. In the fourth individual (#15) there were two overlapping de novo variants. Finally, through deep sequencing, we confirmed that mosaicism was not present in any of the five probands with inherited variants or their parents/siblings (Table S5) .
FANCB RNA analysis reveals aberrant splice and unstable transcripts
Availability of cell lines for all individuals except #5 (c.1928-2A>T) allowed us to analyze the splicing and stability of FANCB transcripts. Aberrant splicing products were observed in 7 individuals 4, 7 and 19. Individual 7, carrying a nonsense variant (c.949C>T; p.Q317*) near the end of exon 3, generated a second transcript that eliminates 74 bp from the end of exon 3 (p.G294Cfs*3) ( Figure 2A ). Individual 4, carrying a canonical splice variant (c.1496+1G>A), generated a frameshift transcript due to skipping of exon 7 (170 bp; p.K443Vfs*4) ( Figure 2B ).
Individual 19, carrying a missense variant in exon7 (c.1435T>G; p.W479G), generated an additional transcript without exon 7 ( Figure 2B ). The relative levels of transcripts with and without exon 7 were 13.5% and 86.5%, respectively ( Figure 2C -E).
The quantitative analysis of the LCL from individual 15 revealed the presence of indel variant transcripts only, while gDNA analysis showed the presence of both the indel and missense variants ( Figure S2A-B ), suggesting that the missense variant transcript is highly unstable. The unstable nature of this variant may be the reason behind the observed positive growth selection for cells with the indel variant from blood to LCL (Table S2 ). Figure 3D ) also revealed variable activity of the variants: L43S showed very little function, L329P was moderate, and W479G and L676P displayed substantial activity. The G750V-complemented cell line showed little function in these assays, however we found that the lentiviral transcript carrying c.2249G>T (G750V) variant was expressed at 3.5-fold lower level than WT FANCB transcript ( Figure S2C ). This resulted in reduced expression of G750V protein, indicating that the c.2249G>T variant destabilizes the 8 transcript. Except for G750V, which shows globally low expression of HA-FANCB, the remaining missense variants also had reduced nuclear localization ( Figure S4 ).
Functional evaluation of constructs expressing missense variants in a FANCB null cell line
Efficiency of missense variants in recombinant FA core complex assembly and in vitro FANCD2:FANCI ubiquitination
To define how FANCB variants directly affected the assembly of the FA core complex and subcomplexes, we utilized an in vitro reconstitution assay and biochemical test of FA core complex assembly and activity in ubiquitination of FANCD2 and FANCI proteins. In addition to the missense variants described above, we included F118S, the only other missense variant reported in the literature, 19 and L717*, the truncation variant missing only the last 142 amino acids. 8 The FA core complex is made up of three subcomplexes: BL100, AG20 and CEF. 20 Baculoviral expression constructs of FA core complex proteins were used for co-expression of either BL100 subcomplex proteins or all the nine proteins of the FA core complex ( Figure 4A ).
Flag-tagged WT and missense variant FANCB protein were used as bait to purify protein complexes, resolved using PAGE, and then the components were quantitated. The assembly of the BL100 subcomplex was not affected by the missense variants, nor the 142 amino acid Cterminal truncation variant (L717*) ( Figure 4B ). However, the L43S and F118S variants showed significantly reduced AG20 and CEF association ( Figure 4C ). Using FFAS-3D, 21 this region of the protein was predicted to have structural homology to other proteins containing beta-propellar structures, a known protein:protein interaction motif. SMURFLite analysis, which predicts betapropellar structures more stringently, 22 concurred with high confidence ( Figure S5 ). The remaining variants, which lie outside of this region, L329P, G750V, and L676P and the L717* truncation, retained WT levels of FA core complex assembly ( Figure 4C ).
Because several variant BL100 complexes failed to properly interact with the remainder of the core complex, we evaluated their effect on in vitro ubiquitination of FANCD2 and FANCI using BL100 complexes purified in isolation and then added to other core complex components ( Figure 5A ). The levels of monoubiquitylation of FANCD2 and FANCI were measured using western blot analysis. As predicted by poor FA core complex assembly, the L43S and F118S variants showed reduced FANCD2 and FANCI monoubiquitination ( Figure 5B ). As previously observed, the kinetics of FANCI monoubiquitination was slower than that for FANCD2, and the N-terminal changes effected both reactions proportionally. The in vitro ubiquitination activity of complexes with L329P and L676P variants resembled WT FANCB for FANCD2 monoubiquitination, however, these had a slower rate of FANCI monoubiquitination ( Figure 5C ). Unexpectedly, given that L717* still forms an intact FA core complex, this truncation variant was 9 completely defective in both FANCD2 and FANCI monoubiquitination, even after a 90 minute incubation period in which equivalent WT and missense variants had attained 100% FANCD2 monoubiquitination. The G750V variant showed near-normal levels of monoubiquitination of both FANCD2 and FANCI, indicating that this variant at protein level may not contribute towards pathogenicity.
Individuals with FANCB pathogenic variants exhibit multiple congenital anomalies, early hematological disease onset and earlier death
Congenital malformations resembling VACTERL-H association were seen in 15/19 (79%) individuals with FANCB variants with the predominant features being renal (R) and limb (L) abnormalities (observed in 13 individuals each) ( Table 1) , which is consistent with previous observations. 7, 23 In general, developmental defects were multiple and severe for the individuals in our study: termination of pregnancy elected for three IFAR individuals diagnosed prenatally, and for one previously reported in the literature, and survival was limited to 0.033, 0.2 and 0.5 month for three other individuals. Interestingly, the three individuals in our cohort without VACTERL-H malformations did not carry truncation variants, which suggests that the residual function of the FA core complex may protect against the most severe developmental defects ( Table 1) To assess the genotype and phenotype correlation, we grouped variants based on the severity of structural alterations in the FANCB protein (WGD/truncation vs. missense). The median time to death was earlier in the WGD/truncation variants group (15.05 months; range 0.03 to 168 months) than in the missense group (104 months; range 45 to 132 months), but was not statistically significant (Log-Rank test = 0.5198, p-value = 0.4709; HR = 1.693 (95% CI: 1 0 0.398 -7.198)) ( Figure 6A ). Similarly, the median time to the hematologic disease was earlier in the WGD/truncation variant group (6.25 months; range 0.25 to 48 months), than in the missense group (43 months; range 12 to 102 months), but was also not statistically significant (Log-Rank test = 2.3962, p value = 0.1216; HR = 3.058 (95% CI: 0.669 -13.973)) ( Figure 6B ). To assess the effect of residual function of missense variants on clinical outcome, we plotted outcomes of the activity of the identified variants and the clinical outcome in the individuals with these variants ( Figure 6C ). Although the number of individuals is small, clinical outcomes appear better with increased residual function of FANCB.
DISCUSSION
Individuals with FANCB pathogenic variants present with a wide spectrum of distinct, de novo or inherited variants
FANCB represents only ~2% of FA individuals, and we describe here 16 FANCB families, each with distinct variants (Figure 1 , Table 1 ). Other previously reported FANCB variants were also only found in single families, 5, 8, 18, 19, [25] [26] [27] [28] [29] [30] suggesting an absence of founder mutations. This is likely due to the short lifespan of male carriers and the severity of symptoms, which probably extends to infertility as in Fancb y/mice. 31 The nature of the variants included large deletion/duplication, missense, nonsense, splice junction, indel, and an unusual combination of overlapping de novo missense and indel variants. Deletions/duplications accounted for 20-30% of all variants in this and other studies. 5, 8, 27 Deletions range from small (~3 kb, removing a single exon 5 ) to large (520kb -590kb, eliminating the entire FANCB gene along with flanking genes, individuals 1-3). Identification of such FANCB variants relies on methods for identifying large deletions such as aCGH. 32 Confirming of the de novo status of FANCB variants, by eliminating the possibility of mosaicism in the parents, requires specialized techniques, such as deep sequencing, which is a robust method to detect unstable variants at low frequencies. In our cases, we found no evidence for mosaicism in probands with de novo and inherited variants, nor heterozygous carrier mothers/siblings (Table S2 and S5). However, for individual 15, who carried two overlapping de novo variants, we observed that the two variants existed at varying frequencies in peripheral blood DNA and the LCL. The reduced fraction of the c.2249G>T (G750V) variant in blood, and to an even greater extent, in LCL suggests that cells carrying indel variant transcript have a selective growth advantage. This could be due to the unstable nature of the missense variant that was observed both in patient LCL cells and in overexpressed FANCB null cells ( Figure 3A and S2) . These findings also suggest that the missense variant originated prior to the indel variant. Observations that 1 1 transcripts differ from predictions based on genomic variants demonstrate the importance of including transcript analysis as a part of comprehensive molecular diagnosis. Figure 6D) . We, and others, have reported earlier that aberrant splicing is associated with certain synonymous, nonsynonymous, and nonsense variants in FA genes 27, 15, 33 indicating that quantitative RNA analysis should be included to evaluate the molecular consequence of a genomic variant, particularly in the absence of clearly pathogenic alterations, but an apparent FA phenotype.
Aberrant splicing from a nonsynonymous variant alters clinical course of the disease
Insight into the molecular function of FANCB from analysis of patient associated variants
Little is known about the actual function of FANCB protein within the FA core complex.
Previous studies showed that the protein is stable for purification only as a recombinant heterodimer with FAAP100. 11 Imaging of the FANCB:FAAP100 complex by EM suggests that the proteins form an intricately intertwined complex containing two of each subunit. We hypothesized that this unusual arrangement could place two FANCL molecules, each in close proximity to the ubiquitination sites of subunit of the FANCD2:FANCI heterodimeric substrate. 12 Interestingly, we find that many variants in FANCB have a greater effect on FANCI monoubiquitination, and only mild or no effect on FANCD2 monoubiquitination in vitro. It is possible that FANCB, as the central dimerization mediator, coordinates the sequential monoubiquitination of FANCD2 and FANCI. Importantly, one of the longest reported truncations in FANCB completely lacks any detectable monoubiquitination activity, even though it retains association with FANCL, FAAP100 and the remainder of the FA core complex. This suggests that the C-terminus of FANCB has an essential role in the catalytic activity of the entire FA core 1 2 complex. From this finding, we can conclude that even small FANCB truncations will be pathogenic.
We also identified two variants in the N-terminus of FANCB that cause an abrogation of interaction with the remainder of the FA core complex. The ~60-80% reduction in core complex association is sufficient to reduce the kinetics of FANCD2 and FANCI monoubiquitination by a similar rate. In a cellular context, where FA core complex concentrations are much more limiting (~0.1 ppm in Protein Abundance Database), 34 such a reduced rate of association is likely to have an even greater effect on FANCD2 monoubiquitination. Together these findings suggest that a predicted beta-propellar in the N-terminus of FANCB mediates association with the FA core complex, while the remainder of the protein mediates the dimerization and catalytic activity of FANCL E3 RING ligase.
Milder clinical presentation relates to the residual function of the FANCB missense variant.
In this study, individuals with WGD/truncation variants in FANCB have more severe phenotypes than individuals with missense variants, although our analyses are limited by small sample sizes (Table 1, Figure 6 A-B) . While it is ideal to perform the time to death analysis with the HSCT status as a time-varying covariate, we do not have a large enough sample size to have a meaningful conclusion from such analysis. Therefore, it was not reported. Results from all the functional assays on missense variants, both from cellular ( Figure 3 ) and in vitro assays ( Figure 4 and 5) as well as transcript analysis are summarized in Table 2 . All of the missense variants tested were found to be pathogenic by one or more assay. In particular, compared to WT FANCB, the majority of variants showed relatively lower levels in the nucleus ( Figure S4 ), which is also a characteristic of pathogenic FANCA missense variants. 33 Together, the functional assays revealed a spectrum of activity, and the cell-based and protein-based assays broadly agreed on the extent of loss of function. The residual effect of each missense variant on cell viability and FANCD2 foci formation appeared to have some correlation with the hematological disease onset and overall survival of the individuals with FANCB missense variants ( Figure 6C ).
Because FANCB is X-linked and, to date, restricted to male cases, each FANCB patient carries only one deleterious allele and a generally more severe form of FA. Our study highlights how complementary approaches to variant analysis converge to provide meaningful new knowledge of both FANCB protein function, and the etiology of FANCB-associated FA. Table 2 . Summary of functional assays for FANCB missense variants. Individual 19 also results in exon 7 skipping along with a normal size product.
(C) Schematics of qf-RT-PCR for relative quantification of transcripts with and without exon 7.
Two FANCB specific forward primers that bind to either exon 7-8 junction or exon 6-8 junction and a reverse primer that bind to exon 8 were designed to amplify products from transcripts with 
